A microsupercapacitor designed by scientists at Rice University that may find its way into personal and even wearable electronics is getting an upgrade. The laser-induced graphene device benefits greatly when boron becomes part of the mix.

Shockwave Medical, Lithoplasty, $40 million, funding, Sofinnova, Venrock

Shockwave Medical announced $40 million in funding, co-led by returning investor Sofinnova Partners and new investor Venrock. Also participating were RA Capital, Deerfield, Sectoral Asset Management, Ally Bridge Group and two undisclosed large-cap strategic investors.

Dassault Systèmes announced during its SIMULIA Community Conference that the first heart model from its “Living Heart Project” will be commercially available on May 29, 2015. Powered by Dassault Systèmes’ 3DEXPERIENCE platform’s realistic simulation applications, the commercial, high-fidelity, scientifically validated 3-D simulator of a four-chamber human heart is the first product of its kind. With this model, device manufacturers, researchers and medical professionals will be able to perform virtual tests and visualize the heart’s response in ways that are not possible with traditional physical testing.

A new study evaluating the Boston Scientific Lotus Valve System demonstrated an extremely low rate of paravalvular aortic regurgitation (leakage) for a transcatheter aortic replacement valve. Study data also showed a cardiovascular mortality rate of less than 2 percent at 30 days.

ART, PBS, pure bioresorbable scaffold, CE Mark

Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next-generation drug-free, pure bioresorbable scaffold used to treat coronary artery disease. The CE Mark was achieved following the completion of extensive pre-clinical research — this included up to three-years of follow-up, and supportive clinical results from leading coronary angioplasty centres such as the Hôpital Européen Georges Pompidou in Paris and investigators such as Jean Fajadet, M.D., at the Clinique Pasteur in Toulouse.

At EuroPCR 2015, Mitralign presented updates on its mitral and tricuspid valve repair systems, including a presentation on six-month data on its Mitral system.

Edwards Lifesciences Corp. announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve demonstrated very low mortality and stroke rates, and no severe paravalvular leaks. These independently adjudicated data from centers in Europe and Canada are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States. The study was presented at EuroPCR 2015 by Alec Vahanian, M.D., chair of the cardiology department at Bichat University Hospital, Paris.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now